

Fall 11-2-2015

# Exometabolome characterization of high cell density culture perfusion and optimization of the cell specific perfusion rate

Veronique Chotteau

*School of Biotechnology, Cell Technology Group, KTH, chotteau@kth.se*

Leila Zamani

*School of Biotechnology, Cell Technology Group, KTH*

Ye Zhang

*School of Biotechnology, Cell Technology Group, KTH*

Magnus Aberg

*Department of Analytical Chemistry, Stockholm University*

Anna Lindahl

*Department of Oncology-Pathology, Science for Life Laboratory and Karolinska Institutet*

*See next page for additional authors*

Follow this and additional works at: [http://dc.engconfintl.org/biomanufact\\_ii](http://dc.engconfintl.org/biomanufact_ii)



Part of the [Biomedical Engineering and Bioengineering Commons](#)

---

## Recommended Citation

Veronique Chotteau, Leila Zamani, Ye Zhang, Magnus Aberg, Anna Lindahl, and Axel Mie, "Exometabolome characterization of high cell density culture perfusion and optimization of the cell specific perfusion rate" in "Integrated Continuous Biomanufacturing II", Chetan Goudar, Amgen Inc. Suzanne Farid, University College London Christopher Hwang, Genzyme-Sanofi Karol Lacki, Novo Nordisk Eds, ECI Symposium Series, (2015). [http://dc.engconfintl.org/biomanufact\\_ii/60](http://dc.engconfintl.org/biomanufact_ii/60)

This Conference Proceeding is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Integrated Continuous Biomanufacturing II by an authorized administrator of ECI Digital Archives. For more information, please contact [franco@bepress.com](mailto:franco@bepress.com).

---

**Authors**

Veronique Chotteau, Leila Zamani, Ye Zhang, Magnus Aberg, Anna Lindahl, and Axel Mie





**SHORT VERSION (i.e. removed several OH's)**  
**Exometabolome characterisation of high cell density culture**  
**perfusion and optimization of the cell specific perfusion rate**

Véronique Chotteau<sup>a</sup>, Leila Zamani<sup>a</sup>, Ye Zhang<sup>a</sup>, Caijuan Zhan<sup>a</sup>,  
 Magnus Aberg<sup>b</sup>, Anna Lindhal<sup>c</sup>, Axel Mie<sup>c</sup>, Pierre-Alain Girod<sup>d</sup>,  
 Alexandra Martiné<sup>d</sup>

*a Cell Technology group (CETEG), KTH, Stockholm, Sweden*  
*b Stockholm University, Stockholm, Sweden*  
*c Karolinska Institutet, Stockholm, Sweden*  
*d Selexis, Switzerland*

Nov 2, 2015 - Integrated Continuous Biomanufacturing II – ECI, Berkeley, CA






KTH Biotechnology

## Outline

- Exometabolome in perfusion culture
- Optimization of perfusion rate
- Conclusions

Nov 2, 2015 – Véronique Chotteau, CETEG, KTH – ECI-Continuous II, Berkeley

3




KTH Biotechnology

CHO #1

## Exometabolome in perfusion culture

Nov 2, 2015 – Véronique Chotteau, CETEG, KTH – ECI-Continuous II, Berkeley

4



## Study in WAVE Bioreactor™ in perfusion with TFF

CHO #1

---


**Goal**

- Study of perfusion in Wave Bioreactor™
- Study of the limits of the system

**System**


- Two types of cell separation based on hollow fiber filtration:
  - Tangential flow filtration – TFF
- IgG production production in CHO cell system, CHO#1
- Application of cryopreservation / cell banking
- Working volume 4L
- Base medium supplemented by feed concentrate (Irvine Scientific, USA)

*Clincke et al 2013a, Clincke et al 2013b*



Nov 2, 2015 – Véronique Chotteau, CETEG, KTH – ECI-Continuous II, Berkeley


5



## Perfusion in Wave™ Bioreactor using TFF at very high cell densities

CHO #1


---



Viability

Viable cell density



214 x 10<sup>6</sup> cells/mL





CHO cells at 200 x 10<sup>6</sup> cells/mL


Nov 2, 2015 – Véronique Chotteau, CETEG, KTH – ECI-Continuous II, Berkeley

6






CHO #2 CHO#3



KTH Biotechnology

Perfusion using ATF in stirred tank bioreactor


Optimization of the perfusion rate





Nov 2, 2015 – Véronique Chotteau, CETEG, KTH – ECI-Continuous II, Berkeley

11

Perfusion in stirred tank bioreactor with ATF



KTH Biotechnology


Ye Zhang Caijuan Zhan

**Goal**

- Better knowledge of the perfusion process → **optimization**



**System**



- IgG production in CHO cell system, CHO #2 (IgG#2), CHO#3 (IgG#3)
- Glass bioreactor - working volume 1L
- ATF2 (Refine)
- Control of perfusion by CytoSys (Iprabio) – 1 run
- Base medium supplemented by feed concentrate (Irvine Scientific, USA)




Nov 2, 2015 – Véronique Chotteau, CETEG, KTH – ECI-Continuous II, Berkeley










**Conclusions**

Nov 2, 2015 – Véronique Chotteau, CETEG, KTH – ECI-Continuous II, Berkeley 18



## Conclusions

---


- Exometabolome foot printing in perfusion showing much higher consistency of the process from cell densities 10 to 200 x 10<sup>6</sup> cells/mL compared to fed-batch
- Observation of current metabolites confirmed by wide MS-based exometabolomics
- Identification of potential biomarkers for the cell density indicated glutathione metabolism modification towards higher cell densities
- Very high cell densities obtained in STR + ATF and other systems using CSPR
- IgG glycosylation not affected by high cell density up to 165 x 10<sup>6</sup> cells/mL and by low CSPR – Importance of CSPR for glycosylation
- CSPR minimized without affecting the cell health but lower IgG productivity

Nov 2, 2015 – Véronique Chotteau, CETEG, KTH – ECI-Continuous II, Berkeley 19



## Acknowledgements

---



**KTH**  
Leila Zamani  
Ye Zhang  
Caijuan Zhan  
Lena Thoring




**Selexis**  
Pierre-Alain Girod  
Alexandra Martiné

**Stockholm University**  
Magnus Aberg



Swedish Governmental  
Agency for Innovation  
Systems

GE Healthcare



**Karolinska Institutet**  
Anna Lindhal  
Axel Mie



Nov 2, 2015 – Véronique Chotteau, CETEG, KTH – ECI-Continuous II, Berkeley 20